Objectif Cardiovascular disease (CVD) is the leading cause of death in Europe and the world. Drugs that lower cholesterol in blood are the most efficient drugs used to date but we are currently still facing a 50-70% residual risk of suffering from CVD. This clearly illustrates an urgent need for the identification, characterization and validation of novel therapeutically relevant targets. Over the last decade, numerous targets have emerged but not led to successful treatment of patients. In addition to missing opportunities of health improvement beyond statins, the 92% failure rate of novel drugs also puts a large burden on the EU economy.While the causal relation between levels of lipids in plasma and CVD forms the basis of this proposal, the challenge taken up by TransCard is ‘Translating disease into Cardiovascular health’: It means that insight into the molecular origin of disturbed lipid metabolism in patients as well as the identification of lipoprotein phenotypes with causal relationships to atherosclerosis can provide immediate targets for pharmaceutical intervention leading to successful treatment of this disease.TransCard will prioritize existing and emerging targets and embark on novel unbiased approaches to identify and prioritize novel key regulators of lipid and lipoprotein metabolism. Achieving this aim will be ensured by a multidisciplinary research consortium of two SMEs and four academic partners who use innovative biotechnological and bioinformatics tools and have direct access to unique biobanks and large-scale population cohorts. This team will also help to translate the basic insight into biology into clinical use by subjecting promising targets from top level basic research to validation of their CVD association in large prospective and patient cohorts. Targets passing these tests will be studied in mice to shed further light on the feasibility of pharmaceutical intervention thereby providing lead targets for further development by other parties. Champ scientifique medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesclinical medicinecardiologycardiovascular diseasesarteriosclerosisnatural sciencesbiological sciencesbiochemistrybiomoleculeslipids Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Thème(s) HEALTH.2013.2.4.2-1 - Discovery research to reveal novel targets for cardiovascular disease treatment Appel à propositions FP7-HEALTH-2013-INNOVATION-1 Voir d’autres projets de cet appel Régime de financement CP-FP - Small or medium-scale focused research project Coordinateur ACADEMISCH ZIEKENHUIS GRONINGEN Contribution de l’UE € 1 554 408,00 Adresse HANZEPLEIN 1 9713 GZ Groningen Pays-Bas Voir sur la carte Région Noord-Nederland Groningen Overig Groningen Type d’activité Higher or Secondary Education Establishments Contact administratif Johanna M. Van Apeldoorn (Ms.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Participants (7) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire ENTELECHON GMBH Participation terminée Allemagne Contribution de l’UE Aucune donnée Adresse St. Veit-Weg 2 93051 REGENSBURG Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Werner Deininger (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée POLYQUANT GMBH Allemagne Contribution de l’UE € 703 153,00 Adresse INDUSTRIESTRASSE 1 93077 BAD ABBACH Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Werner Deininger (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée NEBION AG Suisse Contribution de l’UE € 1 108 900,00 Adresse HOHLSTRASSE 515 8048 Zurich Voir sur la carte Région Schweiz/Suisse/Svizzera Zürich Zürich Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Philip Zimmermann (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée REGION HOVEDSTADEN Danemark Contribution de l’UE € 771 500,00 Adresse KONGENS VAENGE 2 3400 Hillerod Voir sur la carte Région Danmark Hovedstaden Nordsjælland Type d’activité Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments) Contact administratif Christine Nuding (Ms.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM Pays-Bas Contribution de l’UE € 765 800,00 Adresse MEIBERGDREEF 15 1105AZ Amsterdam Voir sur la carte Région West-Nederland Noord-Holland Groot-Amsterdam Type d’activité Higher or Secondary Education Establishments Contact administratif Barry Van Rookhuizen (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée University of Zurich Suisse Contribution de l’UE € 871 000,00 Adresse RAMISTRASSE 71 8006 ZURICH Voir sur la carte Type d’activité Higher or Secondary Education Establishments Contact administratif Arnold Von Eckardstein (Prof.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée ACIES Consulting Group SAS France Contribution de l’UE € 109 882,00 Adresse rue de la République 69 69002 LYON Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Marie-Laure Muiras (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée
